| Indication |
For the treatment of the following infections (respiratory, skin,
soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae,
staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E.
coli, P. mirabilis, Klebsiella sp, coagulase-negative staph |
| Pharmacodynamics |
Cefprozil, a semisynthetic, second-generation cephalosporin, is
used to treat otitis media, soft-tissue infections, and respiratory
tract infections. |
| Mechanism of action |
Cefprozil, like the penicillins, is a beta-lactam antibiotic. By
binding to specific penicillin-binding proteins (PBPs) located inside
the bacterial cell wall, it inhibits the third and last stage of
bacterial cell wall synthesis. Cell lysis is then mediated by bacterial
cell wall autolytic enzymes such as autolysins; it is possible that
cefprozil interferes with an autolysin inhibitor. |
| Absorption |
Oral bioavailability is approximately 95%. |
| Volume of distribution |
|
| Protein binding |
36% |
| Metabolism |
Cefprozil is eliminated primarily by the kidneys |
| Route of elimination |
Not Available |
| Half life |
1.3 hours |
| Clearance |
- 3 mL/min/kg [fasting subjects]
|
| Toxicity |
Single 5000 mg/kg oral doses of cefprozil caused no mortality or
signs of toxicity in adult, weaning or neonatal rats, or adult mice. A
single oral dose of 3000 mg/kg caused diarrhea and loss of appetite in
cynomolgus monkeys, but no mortality. |
